Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $3.1M Series A financing. Participants include Advent Life Sciences.

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $1M Series A financing. Participants include Advent Life Sciences.

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

LanzaTech (New Zeland) a development-stage fermentation and synthetic biology biofuels company, closed a $55.8M Series C financing. Participants include Malaysian Life Sciences Capital Fund, Petronas Technology Ventures, Dialog Group, Khosla Ventures, Qiming Venture Partners and K1W1.

GlySure (United Kingdom) a clinical-stage medical device company focused on a intravascular, optical fluorescence-based sensor for continuous blood glucose monitoring systems, closed a $10.9M Series C financing. Participants include Morningside Venture, Amadeus Capital Partners, Chester Investments and Delta Partners.

BerGenBio (Norway) a preclinical-stage biopharma company focused on receptor tyrosine kinase inhibition for the treatment of cancer, closed a $8.8M Series A financing. Participants include Sarsia Seed and Investinor.

Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.

PolyPid (Israel) a development-stage biotechnology company focused on polymers and lipid-based systems for drug delivery and biodegradable bone void fillers, closed a $2M Series B financing. Participants include Xenia Venture Capital.

Oxitec (England), a clinical-stage biopharmaceutical company focused on dengue fever, closed a $12.7M financing. Participants include Oxford Capital and Asia Pacific Capital.

Innavirvax (France), a biopharmaceutical company focused on therapeutic solutions of pathologies associated with immune deregulation, closed a $4.9M Series B financing. Participants include Pradeyrol Développement, Fa Dièse, CapDecisif Management and FRCI.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...